EVOTEC SE ADR
NASDAQ: EVO (Evotec SE)
Last update: 1 hour ago2.61
-0.01 (-0.38%)
| Previous Close | 2.62 |
| Open | 2.63 |
| Volume | 19,661 |
| Avg. Volume (3M) | 141,185 |
| Market Cap | 934,222,528 |
| Price / Earnings (Forward) | 175.44 |
| Price / Sales | 1.02 |
| Price / Book | 0.980 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -26.26% |
| Operating Margin (TTM) | -9.91% |
| Diluted EPS (TTM) | -0.690 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Total Debt/Equity (MRQ) | 52.48% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | 34.59 M |
| Levered Free Cash Flow (TTM) | -90.11 M |
| Return on Assets (TTM) | -2.42% |
| Return on Equity (TTM) | -20.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Evotec SE | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.0 |
| Average | 1.17 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Institutions | 2.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dcf Advisers, Llc | 31 Dec 2025 | 1,198,993 |
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Optiver Holding B.V. | 31 Dec 2025 | 40,603 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |